Ventana Fenestrated Stent Graft - Prospective, Multicenter, Single Arm Feasibility and Safety Study of the Endologix Fenestrated Stent Graft System for the Endovascular Repair of Juxtarenal/Pararenal (JAA/PAA) Aneurysms
Ventana Fenestrated Stent Graft - Prospective, Multicenter, Single Arm Safety and Effectiveness Trial of the Endologix Fenestrated Stent Graft System for the Endovascular Repair of Juxtarenal/Pararenal (JAA/PAA) Aneurysms
Xpand BX Covered Stent - Product Status
Xpand BX Covered Stent - Product Description
Endologix, Inc., Key Employees
Endologix, Inc., Key Employee Biographies
Endologix, Inc., Subsidiaries
List of Figures
Endologix, Inc. Pipeline Products by Equipment Type
Endologix, Inc. Pipeline Products by Development Stage
Endologix, Inc. Ongoing Clinical Trials by Trial Status
Endologix, Inc. (ELGX) - Product Pipeline Analysis, 2017 Update Description
Endologix, Inc. (Endologix) is a medical device company. It undertakes the development, manufacturing and selling of minimally invasive treatments for aortic diseases. The company lays focus on its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). The company’s AAA products are built on traditional minimally-invasive endovascular repair (EVAR) platform or endovascular sealing (EVAS) platform. The company’s EVAR products include AFX endovascular AAA system Vela Proximal Endograft and Intuitrak endovascular AAA system; and EVAS products comprise Nellix endovascular aneurysm sealing system. It has manufacturing facility in Irvine. The company sells its products to hospitals in the US and Europe through direct sales force and through third-party international distributors and agents in other parts of the world. Endologix is headquartered in California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Endologix, Inc.
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio